compound 22 [PMID: 21823616]   Click here for help

GtoPdb Ligand ID: 8116

Compound class: Synthetic organic
Comment: Compound 22 was a lead reported as the result of a compound screen for inhibitors of the protein kinase integrin-linked kinase (ILK) [9].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 61.67
Molecular weight 533.24
XLogP 6.05
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CNC(=O)CCc1nn(c(c1)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)N1CCNCC1
Isomeric SMILES CNC(=O)CCc1nn(c(c1)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)N1CCNCC1
InChI InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39)
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
ILK is reported to promote oncogenesis and tumour progression by mediating the phosphorylation of other proteins including Akt (protein kinase B), GSK3β and myosin light chain (MLC) [4-6,10-11,14]. Abberant ILK activity has been associated with the pathology of many types of cancers [1-3,7-8,12-13]. These findings make ILK a cogent target for therapeutic inhibition.